Swiss Diversified Financial Stock News

In January 2026, Sandoz confirmed that the European Commission had granted marketing authorization for Ondibta®, a biosimilar insulin glargine pre-filled pen for patients with diabetes aged two and above, matching Lantus® SoloStar® in safety, quality and efficacy. This approval, under Sandoz’s commercialization agreement with Gan & Lee, reinforces its biosimilar footprint in diabetes care and supports broader access to insulin across Europe. We will now examine how this European Commission...

In mid-January 2026, analysts from Kepler Capital and Goldman Sachs reiterated Hold views on Swissquote Group Holding while independent Meyka AI issued a positive rating, citing the company’s AI-driven client automation and personalised trading tools alongside resilient 2025 preliminary results. The commentary underscores how Swissquote’s use of AI, combined with robust net income resilience and ongoing client flows into crypto and margin products, is shaping a differentiated growth story...

Logitech International (SWX:LOGN) has introduced its Rally AI Camera and Rally AI Camera Pro, two AI-powered conference cameras. The new products focus on room usage detection, sustainability features, and integration into managed network environments. The launch marks an expansion of Logitech's video collaboration portfolio aimed at enterprise and education customers. For Logitech, known for its peripherals and video collaboration gear, the Rally AI Camera line extends its presence in...

While SIG Group AG ( VTX:SIGN ) might not have the largest market cap around , it led the SWX gainers with a relatively...

As of January 2026, European markets have shown resilience, with the pan-European STOXX Europe 600 Index rising by 0.77%, buoyed by strong economic data and earnings results. In this context of mixed performance across major indices like Germany's DAX and France's CAC 40, identifying stocks that may be trading below their estimated value involves looking for companies with solid fundamentals that could benefit from ongoing economic recovery and favorable trade conditions.

As the European market shows resilience with the STOXX Europe 600 Index ending higher, supported by robust economic data and earnings results, investors are increasingly drawn to dividend stocks for their potential to provide steady income in uncertain times. In this context, selecting a good dividend stock involves considering factors like consistent payout history and financial stability, which can offer a buffer against market volatility.

Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid. See our latest analysis for Galderma Group. The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...

In January 2026, Chocoladefabriken Lindt & Sprüngli AG issued earnings guidance indicating it expects its 2025 operating profit margin to rise at the lower end of a 20–40 basis point improvement range from the previous year’s 16.2%. The company also projected ongoing annual operating margin improvements of 20–40 basis points from 2026 onwards, underscoring a clear emphasis on gradual profitability enhancement. We will now examine how Lindt & Sprüngli’s focus on steady operating margin...

If you are wondering whether Logitech International's current share price still lines up with its fundamentals, you are not alone. The stock recently closed at US$72.48, with returns of a 6.0% decline over 7 days, a 12.7% decline over 30 days, an 8.8% decline year to date, a 9.6% decline over 1 year, a 40.9% return over 3 years, and a 13.7% decline over 5 years, which can change how investors think about both opportunity and risk. Recent coverage has highlighted Logitech International in...

The Ascom Holding AG ( VTX:ASCN ) share price has done very well over the last month, posting an excellent gain of 32...

Helvetia Baloise Holding (VTX:HBAN) has had a rough month with its share price down 3.7%. But if you pay close...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

It's not a stretch to say that Swiss Life Holding AG's ( VTX:SLHN ) price-to-earnings (or "P/E") ratio of 20.8x right...

When close to half the companies in Switzerland have price-to-earnings ratios (or "P/E's") below 20x, you may consider...

Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high...

While not a mind-blowing move, it is good to see that the Temenos AG ( VTX:TEMN ) share price has gained 23% in the...

Let's talk about the popular Kuehne + Nagel International AG ( VTX:KNIN ). The company's shares saw a significant share...

As the European market shows resilience with the STOXX Europe 600 Index rising by 0.77% amid solid economic data and earnings results, investors are increasingly focusing on dividend stocks to bolster their portfolios. In a climate where stability and income generation are highly valued, selecting dividend stocks that align with robust financial performance and consistent payout histories can be a prudent strategy for enhancing investment portfolios.

Schindler Holding AG ( VTX:SCHN ) saw a double-digit share price rise of over 10% in the past couple of months on the...

The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you...

ARYZTA AG's ( VTX:ARYN ) price-to-earnings (or "P/E") ratio of 12.8x might make it look like a buy right now compared...

Despite an already strong run, Comet Holding AG ( VTX:COTN ) shares have been powering on, with a gain of 33% in the...

Why Cosmo Pharmaceuticals is Back on Investors’ Radars Cosmo Pharmaceuticals (SWX:COPN) is drawing fresh attention after management detailed a scale up phase under its Vision 2030 plan, highlighting solid finances, expanding GI Genius and Winlevi franchises, and a maturing dermatology and gastroenterology pipeline. See our latest analysis for Cosmo Pharmaceuticals. That story around Vision 2030 seems to be resonating with the market, with a 90 day share price return of 75.23% and a 1 year...

Why Zurich Insurance Group’s risk warnings are back in focus Zurich Insurance Group (SWX:ZURN) is back on investors’ radar after senior executives highlighted rising geopolitical, technological, and societal risks, ahead of the group’s upcoming presentation at the Octavian Seminar 2026 in Davos. See our latest analysis for Zurich Insurance Group. Zurich’s share price at CHF 578.8 has slipped over the year to date, yet a 90 day share price return of 4.25% sits alongside a 1 year total...